MonacoTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0 (–) 0 (–)
Mortality (HIV+TB only) 0 (–) 0 (–)
Incidence  (includes HIV+TB) 0 (–) 0 (–)
Incidence (HIV+TB only)        
Incidence (MDR/RR-TB)** 0 (0–0) 0 (0–0)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0 (0–0) 0 (0–0) 0 (0–0)
Males 0 (0–0) 0 (0–0) 0 (0–0)
Total 0 (0–0) 0 (0–0) 0 (–)
TB case notifications, 2015  
Total cases notified 0
Total new and relapse 0
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status  
          - % pulmonary  
          - % bacteriologically confirmed among pulmonary  
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015  
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 null
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 0  
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  0
(0–0)
Estimated % of TB cases with MDR/RR-TB 2.3% (1.4–3.2) 15% (13–18)  
% notified tested for rifampicin resistance     0
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: , XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2014   0
Previously treated cases registered in 2014   0
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013 100% 3
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data